Cosciens closes second tranche of convertible debenture offering, raising total to US$10.71 million

• Cosciens Biopharma closed a second tranche of a non-brokered private placement of 15% unsecured convertible debentures.
• Issued US$ 4.38 million of debentures in the tranche, lifting total issued across two tranches to US$ 10.71 million.
• Offering size remains up to US$ 20 million; additional tranches are expected in coming weeks, subject to closing conditions.
• Second-tranche finders’ fees totaled US$ 100,000 cash, with US$ 35,000 paid in debentures.
• Conversion terms require shareholder approval under TSX rules; a shareholder meeting is to be held within six months.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cosciens Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609161800PRIMZONEFULLFEED9828566) on September 16, 2026, and is solely responsible for the information contained therein.